Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5085943 | 0.85 | SLC6A3 (0.48) | MEN1KMT2ASLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5085939 | 0.83 | KMT2A (0.43) | MEN1KMT2ASLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5087601 | 0.82 | SLC6A2 (0.44) | MEN1KMT2ASLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5126221 | 0.82 | SLC6A3 (0.39) | MEN1KMT2ASLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5132120 | 0.81 | CYP46A1 (0.43) | MEN1KMT2ASLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5125410 | 0.78 | SLC6A3 (0.35) | MEN1KMT2ASLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5125529 | 0.76 | SLC6A3 (0.41) | SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL5093741 | 0.75 | SLC6A2 (0.46) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5093763 | 0.74 | SLC6A3 (0.39) | SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL5132149 | 0.74 | SLC6A3 (0.42) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580965-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249128-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, NPSR1 | MEN1 1340/4885KMT2A 2892/4885SLC6A3 1577/4885 |
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | MEN1 4132/4885KMT2A 1749/4885SLC6A3 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.